Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans

Journal of Endocrinological Investigation

Volumn 32, Issue 3, 2009, Pages 267-271

  Zanotti Fregonara, P ^a   Keller, I ^b   Rubello, D ^c   Calzada Nocaudie, M ^b   Devaux, J Y ^b   Hindie E ^d  

^a DIF   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

131I therapy; 131I whole body scan; Thyroid cancer; TSH levels

Indexed keywords

IODINE 131; LIOTHYRONINE; THYROGLOBULIN; THYROTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOTHYROIDISM; MALE; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; TUMOR RECURRENCE; WHOLE BODY SCINTISCANNING;

EID: 67651251503     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346465     Document Type: Article

References (16)

1. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 1433-1441 (Pubitemid 36623351)
2. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004, 150: 105-112 (Pubitemid 38312801)
3. 131I therapy for elevated thyroglobulin levels. Thyroid 1997, 7: 273-276 (Pubitemid 27190595)
4. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987, 28: 1888-1891 (Pubitemid 18017100)
5. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001, 86: 4092-4097
6. de Keizer B, Koppeschaar HP, Zelissen PM, et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001, 28: 198-202. (Pubitemid 32186635)
7. 131I whole-body scan: comparative study. Clin Endocrinol (Oxf) 2003, 58: 421-427 (Pubitemid 36390613)
8. Wilson LM, Barrington SF, Morrison ID, Kettle AG, O'Doherty MJ, Coakley AJ. Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med 1998, 25: 622-628 (Pubitemid 28297837)
9. Hindié E, Zanotti-Fregonara P, Duron F, Keller I, Bouchard P, Devaux JY. Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131? Clin Endocrinol (Oxf) 2007, 66: 329-334
10. Waxman A, Ramanna L, Chapman N, et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981, 22: 861-865 (Pubitemid 11020541)
11. Vagenakis AG, Braverman LE, Azizi F, Portinay GI, Ingbar SH. Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. N Engl J Med 1975, 293: 681-684
12. Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977, 50: 799-807. (Pubitemid 8212220)
13. 131I in thyroid cancer. Lancet 1994, 344: 1501-1502 (Pubitemid 24351712)
14. 131I whole-body scanning. J Nucl Med 2005, 46: 1473-1480 (Pubitemid 46173259)
15. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81: 4318-4323 (Pubitemid 26412036)
16. Zanotti-Fregonara P, Toubert ME, Taieb D, Ravasi L, Rubello D, Hindie E. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Minerva Endocrinol 2008, 33: 53-65.